Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2002 Jun;133(6):836-7.
doi: 10.1016/s0002-9394(02)01418-6.

Additive intraocular pressure lowering effect of various medications with latanoprost

Affiliations

Additive intraocular pressure lowering effect of various medications with latanoprost

Daniel J O'Connor et al. Am J Ophthalmol. 2002 Jun.

Abstract

Purpose: To determine the additive intraocular pressure reduction of various topical glaucoma agents used adjunctively with latanoprost.

Design: Retrospective interventional case series.

Methods: Retrospective evaluation of 73 eyes of 73 patients with glaucoma and inadequate intraocular pressure control on latanoprost alone. Each patient received adjunctive treatment with an additional glaucoma agent (dorzolamide, brimonidine, timolol, or other beta-blockers) for 1 year.

Results: When added to latanoprost, dorzolamide lowered intraocular pressure an additional 3.9 mm Hg (19.7%, P <.001); beta-blockers further reduced intraocular pressure by 2.0 mm Hg (12.3%, P <.001), and brimonidine further reduced intraocular pressure by 2.0 mm Hg (9.3%, P =.0011). Dorzolamide dosed twice or three times daily was as effective as adjunctive therapy with latanoprost (P =.92).

Conclusion: Adjunctive therapy with dorzolamide provided a statistically significant intraocular pressure reduction at 1 year in eyes that were inadequately controlled with latanoprost alone.

PubMed Disclaimer

MeSH terms

LinkOut - more resources